Genevieve Kumapley, PharmD, BCOP, reflects on the significant out-of-pocket (OOP) costs associated with oral oncolytics and suggests how a change in benefit design can help patients afford the treatments they need.
“[Under the prescription benefit,] patients are required to now cover anywhere from 25% to 30% of costs, notes Dr Kumapley. “That’s significant.”
High costs burden patients and affect their adherence to treatment, remarks Dr Kumapley. For instance, patients prescribed high-cost drugs are less likely to fill their prescriptions, and although patient assistance programs are available to assist patients with the costs of treatment, drug benefit design should be reevaluated.
Dr Kumapley explains that currently, while intravenous therapies are covered under the medical benefit, oral oncolytics are covered under the prescription benefit. There is a large disparity in patient OOP cost, with the patient responsible for a higher cost under the prescription benefit. In oncology, she adds, coverage of oral oncolytics under the medical benefit may be more beneficial in terms of reduced patient OOP cost.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Closing the Gaps in Cardiac Care With Technology, Collaboration
March 12th 2025Cardiologists, primary care physicians, and value-based care leaders convened in Phoenix, Arizona, on November 12, 2024, to share case studies and insights on how to align cardiology with the principles of value-based care, including through the application of digital tools.
Read More
Overdiagnosis of Adult ADHD Is Exacerbating the Stimulant Shortage
March 11th 2025The authors argue that the stimulant shortage is being perpetuated by the overdiagnosis of attention-deficit/hyperactivity disorder (ADHD) in adults because executive functioning deficits are not included in diagnostic criteria.
Read More